EBS: Emergent BioSolutions, Inc.
About
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.
Current Value
$8.211 Year Return
Current Value
$8.211 Year Return
Key Details
Market Cap
$448.10M
P/E Ratio
-2.02
1Y Stock Return
295.69%
1Y Revenue Growth
1.93%
Dividend Yield
0.00%
Price to Book
0.9
Strategies that include EBS
Stock's related to EBS
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ASPN | 47.94% | $1.16B | +33.90% | 0.00% |
| BHE | 40.88% | $1.70B | +86.81% | 1.41% |
| THRM | 40.00% | $1.28B | -10.01% | 0.00% |
| PRDO | 37.77% | $1.73B | +56.77% | 1.74% |
| PGEN | 35.78% | $228.91M | -28.00% | 0.00% |
| ONEW | 35.61% | $281.57M | -26.61% | 0.00% |
| IOVA | 35.29% | $2.50B | +58.41% | 0.00% |
| ODP | 34.45% | $777.35M | -46.62% | 0.00% |
| VSAT | 34.41% | $876.93M | -65.78% | 0.00% |
| MRNA | 33.78% | $14.35B | -51.66% | 0.00% |
| HCAT | 32.99% | $458.79M | 0.00% | 0.00% |
| BLCO | 32.83% | $6.88B | +28.20% | 0.00% |
| EDIT | 32.73% | $204.72M | -75.49% | 0.00% |
| VTYX | 32.60% | $125.87M | -23.61% | 0.00% |
| SGC | 32.26% | $261.95M | +41.61% | 4.32% |
| NVRO | 32.13% | $158.88M | -73.60% | 0.00% |
| RAPT | 30.76% | $37.41M | -92.14% | 0.00% |
| REGN | 30.70% | $81.82B | -6.79% | 0.00% |
| SHYF | 30.65% | $460.16M | +20.72% | 1.50% |
| CLPT | 30.21% | $302.60M | +84.68% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| APPN | 0.08% | $2.72B | -0.51% | 0.00% |
| TW | 0.08% | $28.66B | +42.39% | 0.29% |
| NERV | 0.09% | $14.69M | -58.00% | 0.00% |
| BKD | -0.12% | $1.04B | -2.44% | 0.00% |
| ERII | 0.14% | $888.67M | -20.30% | 0.00% |
| HDSN | -0.16% | $260.34M | -54.39% | 0.00% |
| BYRN | -0.16% | $479.70M | +295.19% | 0.00% |
| WM | 0.16% | $87.92B | +27.58% | 1.34% |
| LLY | 0.18% | $692.74B | +23.14% | 0.71% |
| TDOC | -0.19% | $1.54B | -47.22% | 0.00% |
| CYCN | -0.20% | $4.77M | -16.19% | 0.00% |
| TSLX | 0.22% | - | - | 9.30% |
| DASH | 0.31% | $73.18B | +86.24% | 0.00% |
| PLMR | -0.33% | $2.84B | +79.77% | 0.00% |
| MNOV | -0.34% | $93.19M | +2.15% | 0.00% |
| MNDY | -0.45% | $12.81B | +50.66% | 0.00% |
| FWONK | 0.47% | $20.20B | +25.99% | 0.00% |
| BROS | -0.53% | $5.67B | +74.77% | 0.00% |
| LFVN | 0.53% | $169.84M | +130.61% | 1.10% |
| LTM | -0.54% | $8.51B | -100.00% | <0.01% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VSTS | -24.94% | $1.76B | -18.18% | 1.04% |
| PANW | -24.35% | $126.99B | +46.98% | 0.00% |
| MCK | -23.36% | $78.15B | +35.51% | 0.42% |
| FTNT | -16.58% | $69.59B | +72.67% | 0.00% |
| NTGR | -14.92% | $695.37M | +91.07% | 0.00% |
| CBOE | -14.82% | $21.46B | +15.84% | 1.11% |
| FSLY | -14.71% | $941.41M | -61.50% | 0.00% |
| COR | -13.46% | $47.48B | +21.20% | 0.86% |
| MFIN | -13.45% | - | - | 4.31% |
| DT | -12.54% | $15.40B | -1.30% | 0.00% |
| PGR | -11.81% | $149.10B | +57.29% | 0.45% |
| HRTG | -10.08% | $371.89M | +58.22% | 0.00% |
| DRVN | -9.99% | $2.68B | +26.39% | 0.00% |
| MNST | -9.97% | $52.25B | -1.95% | 0.00% |
| FROG | -9.64% | $3.34B | +11.67% | 0.00% |
| IMNN | -9.41% | $10.02M | -22.89% | 0.00% |
| EZPW | -9.18% | $655.76M | +45.24% | 0.00% |
| SPNT | -9.14% | $2.41B | +43.68% | 0.00% |
| NOC | -8.67% | $71.54B | +4.23% | 1.60% |
| HIHO | -8.45% | $8.63M | 0.00% | 6.12% |
ETF's related to EBS
News
Finnhub
A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic Republic of Congo...
Yahoo
Emergent BioSolutions ( NYSE:EBS ) Third Quarter 2024 Results Key Financial Results Revenue: US$293.8m (up 8.6% from 3Q...
Yahoo
Emergent BioSolutions Inc (EBS) reports a robust financial performance with a 9% revenue increase and significant debt reduction, despite challenges in Narcan sales.
SeekingAlpha
Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a long-term Buy rating for EBS stock.
Yahoo
On Thursday, Emergent BioSolutions Inc. (NYSE:EBS) stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa. The company reported third-quarter sales of $293.8 million, up 9% year over year, with the management guidance of $265 million–$315 million, and missing the consensus of $297.5 million. The company reported an adjusted EPS of $1.37, a turnaround from a loss of $1.09 a year ago, beating the consensus of $0.14. Revenues from Narcan (naloxone HCl) Nasal Spray de
Yahoo
EBS earnings call for the period ending September 30, 2024.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.